Beat the Blues in Pregnancy Study - Transcranial Magnetic Stimulation
| Status: | Completed |
|---|---|
| Conditions: | Depression, Major Depression Disorder (MDD) |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 39 |
| Updated: | 4/17/2018 |
| Start Date: | November 2011 |
| End Date: | January 2017 |
Transcranial Magnetic Stimulation (TMS) in Pregnant Women With Depressive Disorder
The purpose of this study is to determine if repetitive transcranial magnetic stimulation
(TMS) will alleviate symptoms of major depressive disorder (MDD) in pregnant women.
TMS uses electromagnetic impulses to encourage neurons in the brain to communicate more
effectively with one another. Effective neuron communication is thought to lead to the
lessening of depressive symptoms. In this study subjects require daily TMS treatment for
approximately four weeks.
(TMS) will alleviate symptoms of major depressive disorder (MDD) in pregnant women.
TMS uses electromagnetic impulses to encourage neurons in the brain to communicate more
effectively with one another. Effective neuron communication is thought to lead to the
lessening of depressive symptoms. In this study subjects require daily TMS treatment for
approximately four weeks.
We hypothesize that there will be a decline in the Hamilton Rating Scale for Depression
(HDRS-17) scores from the beginning to end of treatment. We expect that this decrease will be
significantly greater in subjects receiving active transcranial magnetic stimulation (TMS)
compared to those receiving placebo TMS. Treatment response will be defined as greater than
50% reduction in HDRS-17 score.
We also hypothesize that levels of Brain Derived Neurotrophic Factor (BDNF), a protein
thought to regulate mood and cognitive functioning, will increase in subjects who respond to
TMS treatment. We expect BDNF levels to increase by greater than or equal to 20% in those who
respond to TMS. As previously stated, TMS response will be defined as a significant decrease
(50% or greater) in the HDRS-17 from baseline to end of treatment.
(HDRS-17) scores from the beginning to end of treatment. We expect that this decrease will be
significantly greater in subjects receiving active transcranial magnetic stimulation (TMS)
compared to those receiving placebo TMS. Treatment response will be defined as greater than
50% reduction in HDRS-17 score.
We also hypothesize that levels of Brain Derived Neurotrophic Factor (BDNF), a protein
thought to regulate mood and cognitive functioning, will increase in subjects who respond to
TMS treatment. We expect BDNF levels to increase by greater than or equal to 20% in those who
respond to TMS. As previously stated, TMS response will be defined as a significant decrease
(50% or greater) in the HDRS-17 from baseline to end of treatment.
Inclusion Criteria:
- Subjects are capable of giving written informed consent and complying with all study
procedures;
- Female age 18-39 years old at date of enrollment;
- Pregnant, weeks 14-34;
- Current Depressive Symptoms;
- No change in antidepressant medication at least two weeks prior to study entry if
using an antidepressant.
Exclusion Criteria:
- Any alcohol or drug abuse/dependence over the 6 months prior to study entry;
- History of a seizure disorder in subject or first degree relative;
- Anti-psychotic, lithium, or anti-convulsant medications within 2 weeks of study
enrollment;
- History of known brain lesions, or severe head trauma;
- Subjects with any metallic object implanted in the skull;
- Subjects with significant cardiac disease;
- Neurological or psychiatric disorders;
- Serious medical illnesses that may compromise patient safety or study conduct;
- Currently taking a drug with known potential for fetal toxicity;
- Previous pregnancy with an adverse fetal outcome;
- Current obstetrical complications
- Actively suicidal;
- History of depression unresponsive to treatment with electroconvulsive therapy (ECT).
We found this trial at
1
site
Click here to add this to my saved trials
